HB0043, the world’s first dual-antibody drug targeting IL-17A and IL-36R, has been approved for clinical trials
August 1, 2025
Source: drugdu
150
On July 31, Huahai Pharmaceutical announced that its subsidiaries, Huaotai and Huabo Bio, received approval from the National Medical Products Administration (NMPA) for the clinical trial approval of HB0043 for injection. HB0043 is a recombinant humanized IgG1 bispecific antibody targeting human interleukin-17A (IL-17A) and the human interleukin-36 receptor (IL-36R). It exhibits high binding and blocking activity and is being developed for the treatment of various autoimmune diseases. HB0043 is the world's first bispecific drug targeting both IL-17A and IL-36R.
Compared with monoclonal antibodies, HB0043 has a stronger inhibitory effect on cytokine-induced inflammation and fibrosis responses. Through dual blockade of IL-17A and IL-36R, it has demonstrated stronger efficacy than monoclonal antibodies in various animal disease models such as atopic dermatitis (AD), idiopathic pulmonary fibrosis (IPF), diabetic nephropathy (DN), and neutrophilic asthma.
Source：https://www.nbd.com.cn/articles/2025-07-31/3997363.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Breaking the Mold and Forging a New Path! From Insulin Technology Pioneer to Global Innovation Competitor December 4, 2025
- A subsidiary of Kingfriend Pharmaceutical Co., Ltd. has received FDA approval for its self-developed injectable dapavancin December 4, 2025
- Major ophthalmic new drug successfully completed Phase III trials December 4, 2025
- Simcere Pharmaceutical and Wangshan Wangshui have reached an exclusive licensing agreement for deuterium remidevir hydrobromide for new indications such as RSV infection December 4, 2025
- SAL0140 tablets approved for clinical trials for the treatment of chronic kidney disease December 4, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
